Search Results
Trastuzumab + pertuzumab may improve pCR outcomes in HER2-positive breast cancer patients
A presurgery combination therapy may improve outcomes for women with HER2 positive breast cancer
Dr. Tripathy on Neoadjuvant Treatment Strategies in HER2+ Breast Cancer
Leveraging Targeted Therapies to Improve Outcomes Across the Continuum of HER2+ Breast Cancer
Optimizing Therapy in HER2+ Disease with Dr. Hope S. Rugo
Impact of biomarkers on pCR and survival after T-DM1 with or without ET vs trastuzumab and ET in...
New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Irene and Dr. Vogel
New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Meisel & Dr. Soliman
Current Treatment Options for Patients With HER2-Positive Metastatic Breast Cancer
New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Mahtani & Dr. Schwartzberg
New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Bagegni & Dr. Gradishar
Adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for HER2-positive breast cancer
